PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $137 | -11.6% | 13,235 | +22.4% | 0.00% | – |
Q2 2023 | $155 | +74.2% | 10,813 | -13.7% | 0.00% | – |
Q1 2023 | $89 | -11.0% | 12,526 | +41.1% | 0.00% | – |
Q4 2022 | $100 | -99.1% | 8,879 | +809.7% | 0.00% | – |
Q3 2022 | $11,000 | -72.5% | 976 | -79.5% | 0.00% | – |
Q2 2022 | $40,000 | -57.4% | 4,767 | -31.6% | 0.00% | – |
Q1 2022 | $94,000 | – | 6,967 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Medicxi Ventures Management (Jersey) Ltd | 2,484,274 | $27,873,554 | 11.71% |
Frazier Life Sciences Management, L.P. | 8,407,152 | $94,328,245 | 5.86% |
Abingworth LLP | 1,435,106 | $16,101,889 | 5.25% |
Opaleye Management Inc. | 417,500 | $4,684,350 | 1.63% |
683 Capital Management, LLC | 1,350,000 | $15,147,000 | 1.28% |
Newtyn Management, LLC | 484,074 | $5,431,310 | 1.12% |
Penn Mutual Asset Management | 62,802 | $704,638 | 0.79% |
StepStone Group LP | 422,085 | $4,735,794 | 0.62% |
MPM BioImpact LLC | 195,942 | $2,198,469 | 0.57% |
Avidity Partners Management LP | 1,900,000 | $21,318,000 | 0.46% |